The Safety Rates Drug Report

Member Login
2004.Q1    2004.Q2    2004.Q3    2004.Q4    2005.Q1    2005.Q2    2005.Q3    2005.Q4    2006.Q1    2006.Q2    2006.Q3    2006.Q4    2007.Q1    2007.Q2    2007.Q3    2007.Q4    2008.Q1    2008.Q2    2008.Q3    2008.Q4    2009.Q1    2009.Q2    2009.Q3    2009.Q4    2010.Q1    2010.Q2    2010.Q3    2010.Q4    2011.Q1    2011.Q2    2011.Q3    2011.Q4    2012.Q1    2012.Q2    2012.Q3    2012.Q4    2013.Q1    2013.Q2    2013.Q3    2013.Q4    2014.Q1    2014.Q2    2014.Q3    2014.Q4    2015.Q1    2015.Q2    2015.Q3    2015.Q4    2016.Q1    2016.Q2    2016.Q3   

Drug     Injury     Quarter    

Person who experienced the adverse event (patient)

Event ID CASEID CASEVERSION I F COD EVENT DT MFR DT INIT FDA DT FDA DT REPT COD AUTH NUM MFR NUM MFR SNDR LIT REF AGE AGE COD AGE GRP GNDR COD E SUB WT WT COD REPT DT TO MFR OCCP COD REPORTER COUNTRY OCCR COUNTRY
127413181 12741318 1 I 20120331 20160914 20160914 EXP US-ROCHE-1055695 ROCHE 72.00 YR M Y 84.00000 KG 20160914 MD US US

Drug(s) used by person

Event ID CASEID DRUG SEQ ROLE COD DRUGNAME PROD AI VAL VBM ROUTE DOSE VBM CUM DOSE CHR CUM DOSE UNIT DECHAL RECHAL LOT NUM EXP DT NDA NUM DOSE AMT DOSE UNIT DOSE FORM DOSE FREQ
127413181 12741318 1 PS Bevacizumab BEVACIZUMAB 1 Intravenous (not otherwise specified) OVER 30 TO 90 MINUTES, ON DAY 1 AND 15 FOR EVERY CYCLE??COURSE 1 U 125085 10 MG/KG
127413181 12741318 2 SS Bevacizumab BEVACIZUMAB 1 Intravenous (not otherwise specified) COURSE 2 U 125085 850 MG
127413181 12741318 3 SS Bevacizumab BEVACIZUMAB 1 Intravenous (not otherwise specified) COURSE 3 U 125085 900 MG
127413181 12741318 4 SS Bevacizumab BEVACIZUMAB 1 Intravenous (not otherwise specified) COURSE 4 U 125085 1800 MG
127413181 12741318 5 SS TEMSIROLIMUS TEMSIROLIMUS 1 Intravenous (not otherwise specified) ON DAYS 1,8, 15, 22 OF EVENT CYCLE?COURSE 1 U 0 25 MG
127413181 12741318 6 SS TEMSIROLIMUS TEMSIROLIMUS 1 Intravenous (not otherwise specified) COURSE 2 U 0 75 MG
127413181 12741318 7 SS TEMSIROLIMUS TEMSIROLIMUS 1 Intravenous (not otherwise specified) COURSE 3 U 0 80 MG
127413181 12741318 8 SS TEMSIROLIMUS TEMSIROLIMUS 1 Intravenous (not otherwise specified) COURSE 4 U 0 80 MG
127413181 12741318 9 SS TEMSIROLIMUS TEMSIROLIMUS 1 Intravenous (not otherwise specified) COURSE 5 U 0 45 MG
127413181 12741318 10 SS TEMSIROLIMUS TEMSIROLIMUS 1 Intravenous (not otherwise specified) COURSE 6 U 0 60 MG
127413181 12741318 11 SS TEMSIROLIMUS TEMSIROLIMUS 1 Intravenous (not otherwise specified) COURSE 7 U 0 60 MG
127413181 12741318 12 SS TEMSIROLIMUS TEMSIROLIMUS 1 Intravenous (not otherwise specified) COURSE 8 U 0 60 MG
127413181 12741318 13 SS TEMSIROLIMUS TEMSIROLIMUS 1 Intravenous (not otherwise specified) COURSE 9 U 0 45 MG
127413181 12741318 14 SS TEMSIROLIMUS TEMSIROLIMUS 1 Intravenous (not otherwise specified) COURSE 10 U 0 15 MG

Indications of drugs used

Event ID CASEID INDI DRUG SEQ INDI PT
127413181 12741318 1 Pancreatic neoplasm
127413181 12741318 5 Pancreatic neoplasm

Outcome of event

Event ID CASEID OUTC COD
127413181 12741318 OT

Reactions reported

Event ID CASEID DRUG REC ACT PT
127413181 12741318 Blood bilirubin increased
127413181 12741318 Hyperglycaemia
127413181 12741318 Hypoalbuminaemia
127413181 12741318 Lymphocyte count decreased

Reporting Sources (this data is often not reported and may therefore be missing here)

no results found

Therapies reported

Event ID CASEID DSG DRUG SEQ START DT END DT DUR DUR COD
127413181 12741318 1 20101117 0
127413181 12741318 2 20101216 0
127413181 12741318 3 20110114 0
127413181 12741318 4 20110211 0
127413181 12741318 5 20101117 0
127413181 12741318 6 20101216 0
127413181 12741318 7 20110114 0
127413181 12741318 8 20110211 0
127413181 12741318 9 20110316 0
127413181 12741318 10 20110406 0
127413181 12741318 11 20110504 0
127413181 12741318 12 20110601 0
127413181 12741318 13 20110629 0
127413181 12741318 14 20110727 0